Fig. 5From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidityNon-cardiovascular death without SVD-related complications. Percentage of hospital admissions with cancer and non-cardiac diseases within the three different groups. Group 1: Cardiovascular death due to SVD; Group 2: Cardiovascular death with no SVD; Group 3: Non-cardiovascular death without SVDBack to article page